Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC

Evangeline Samuel; Gabrielle Lie; Adithya Balasubramanian; Alison Hiong; Yeojeong So; Mark Voskoboynik; Maggie Moore; Mark Shackleton; Andrew Haydon; Tom John; Paul L.R. Mitchell; Ben Markman; Peter Briggs; Sagun Parakh

doi:10.1016/j.cllc.2020.06.001

Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC

Evangeline Samuel, Gabrielle Lie, Adithya Balasubramanian, Alison Hiong, Yeojeong So, Mark Voskoboynik, Maggie Moore, Mark Shackleton, Andrew Haydon, Tom John, Paul L.R. Mitchell, Ben Markman, Peter Briggs, Sagun Parakh

Research output: Contribution to journal › Article › Research › peer-review

17 Citations (Scopus)

Abstract

There are limited data examining the impact of radiotherapy (RT) on the efficacy of checkpoint inhibitors in patients with metastatic non–small-cell lung cancer (NSCLC). In this study, we aimed to evaluate the impact of RT on the efficacy and toxicity of anti-programmed death 1 treatment in patients with metastatic NSCLC treated in a nonclinical trial setting. Our findings show that in patients with metastatic NSCLC, the addition of RT to immune checkpoint inhibitors was not associated with increased toxicity or improved survival.

Original language	English
Pages (from-to)	e425-e430
Number of pages	6
Journal	Clinical Lung Cancer
Volume	22
Issue number	3
DOIs	https://doi.org/10.1016/j.cllc.2020.06.001
Publication status	Published - May 2021

Keywords

Abscopal effect
anti- PD-1 inhibitors
Immune related adverse events
Immunotherapy
Metastatic NSCLC

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cllc.2020.06.001

Cite this

Samuel, E., Lie, G., Balasubramanian, A., Hiong, A., So, Y., Voskoboynik, M., Moore, M., Shackleton, M., Haydon, A., John, T., Mitchell, P. L. R., Markman, B., Briggs, P., & Parakh, S. (2021). Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. Clinical Lung Cancer, 22(3), e425-e430. https://doi.org/10.1016/j.cllc.2020.06.001

@article{6ca193cbb11c47e398005bb600e42d83,

title = "Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC",

abstract = "There are limited data examining the impact of radiotherapy (RT) on the efficacy of checkpoint inhibitors in patients with metastatic non–small-cell lung cancer (NSCLC). In this study, we aimed to evaluate the impact of RT on the efficacy and toxicity of anti-programmed death 1 treatment in patients with metastatic NSCLC treated in a nonclinical trial setting. Our findings show that in patients with metastatic NSCLC, the addition of RT to immune checkpoint inhibitors was not associated with increased toxicity or improved survival.",

keywords = "Abscopal effect, anti- PD-1 inhibitors, Immune related adverse events, Immunotherapy, Metastatic NSCLC",

author = "Evangeline Samuel and Gabrielle Lie and Adithya Balasubramanian and Alison Hiong and Yeojeong So and Mark Voskoboynik and Maggie Moore and Mark Shackleton and Andrew Haydon and Tom John and Mitchell, {Paul L.R.} and Ben Markman and Peter Briggs and Sagun Parakh",

year = "2021",

month = may,

doi = "10.1016/j.cllc.2020.06.001",

language = "English",

volume = "22",

pages = "e425--e430",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC

AU - Samuel, Evangeline

AU - Lie, Gabrielle

AU - Balasubramanian, Adithya

AU - Hiong, Alison

AU - So, Yeojeong

AU - Voskoboynik, Mark

AU - Moore, Maggie

AU - Shackleton, Mark

AU - Haydon, Andrew

AU - John, Tom

AU - Mitchell, Paul L.R.

AU - Markman, Ben

AU - Briggs, Peter

AU - Parakh, Sagun

PY - 2021/5

Y1 - 2021/5

N2 - There are limited data examining the impact of radiotherapy (RT) on the efficacy of checkpoint inhibitors in patients with metastatic non–small-cell lung cancer (NSCLC). In this study, we aimed to evaluate the impact of RT on the efficacy and toxicity of anti-programmed death 1 treatment in patients with metastatic NSCLC treated in a nonclinical trial setting. Our findings show that in patients with metastatic NSCLC, the addition of RT to immune checkpoint inhibitors was not associated with increased toxicity or improved survival.

AB - There are limited data examining the impact of radiotherapy (RT) on the efficacy of checkpoint inhibitors in patients with metastatic non–small-cell lung cancer (NSCLC). In this study, we aimed to evaluate the impact of RT on the efficacy and toxicity of anti-programmed death 1 treatment in patients with metastatic NSCLC treated in a nonclinical trial setting. Our findings show that in patients with metastatic NSCLC, the addition of RT to immune checkpoint inhibitors was not associated with increased toxicity or improved survival.

KW - Abscopal effect

KW - anti- PD-1 inhibitors

KW - Immune related adverse events

KW - Immunotherapy

KW - Metastatic NSCLC

UR - http://www.scopus.com/inward/record.url?scp=85089252946&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2020.06.001

DO - 10.1016/j.cllc.2020.06.001

M3 - Article

C2 - 32778511

AN - SCOPUS:85089252946

SN - 1525-7304

VL - 22

SP - e425-e430

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 3

ER -

Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this